The persistent challenges of healthcare prior authorization are prompting a new wave of technological solutions, with the U.S. government now piloting a program that utilizes artificial intelligence (AI) to streamline insurance coverage decisions. This initiative, part of a broader effort to curb unnecessary medical spending, aims to leverage AI’s processing power to expedite approvals for straightforward claims, thereby potentially reducing the often-frustrating delays patients and physicians encounter. However, the introduction of AI into this complex process is not without controversy, sparking debate about its potential to either alleviate or exacerbate existing issues within the healthcare system.
The Thorny Landscape of Prior Authorization
For many patients and healthcare providers, the process of obtaining pre-approval for recommended medical care has become a significant source of stress and inefficiency. Prior authorization, a mechanism by which health insurers review and approve certain medical services, procedures, or prescription drugs before they are rendered, is intended to act as a safeguard against overuse and unnecessary costs. Yet, in practice, it frequently leads to substantial delays, forcing patients to postpone or even abandon treatments deemed medically necessary by their physicians. These delays can have serious consequences, impacting patient health outcomes and adding to the administrative burden on healthcare providers.
Anecdotal evidence and numerous reports highlight the tribulations patients face. Stories abound of individuals navigating a labyrinth of paperwork and waiting periods, often experiencing worsening health conditions while awaiting insurer approval. The American Medical Association (AMA) has consistently voiced concerns from its physician members regarding these delays. A 2025 survey by the AMA revealed that a significant majority of doctors believe prior authorization processes lead to care interruptions and that patients may abandon recommended treatments due to the protracted waiting times. The appeal process, often the only recourse for denied claims, further prolongs the ordeal, demanding additional time and effort from already strained patients and providers.
AI’s Promise and Peril in Healthcare Approvals
The advent of artificial intelligence presents a potential solution to some of these deeply entrenched problems. AI’s capacity to analyze vast datasets rapidly and identify patterns could theoretically allow for the swift approval of claims that clearly meet established coverage criteria. This would free up human reviewers to focus on more complex cases and, in turn, reduce the time patients spend waiting for essential medical interventions. The theoretical expedited nature of these AI-driven approvals could significantly improve patient access to care.
However, the integration of AI into prior authorization is met with considerable skepticism and apprehension. Critics worry that AI, if not implemented with stringent oversight and ethical considerations, could lead to an increase in wrongful denials. The same AMA survey indicated that 61 percent of physicians fear that AI will exacerbate the denial of necessary treatments. This concern stems from the potential for AI algorithms to be programmed with biases or to operate in ways that prioritize cost containment over clinical necessity, inadvertently creating new barriers to care.
The AMA advocates for greater transparency in how AI is used for prior authorization, pushing for insurers to provide detailed clinical reasoning for any denial and to make their AI algorithms more understandable. This push for transparency is crucial, as health policy analysts like Camm Epstein have stated, "AI should be used to make appropriate care easier to approve, not necessary care easier to deny."
Government Initiatives and Evolving Policies
In an effort to address these issues, the U.S. government has been exploring and piloting AI-driven solutions. The Trump administration initiated a program in six states designed to utilize AI to reduce unnecessary medical spending. This program, known as the Wasteful and Inappropriate Service Reduction Model (WISeR), began in January 2024 and is scheduled to run through December 2031. WISeR aims to identify and mitigate waste and fraud within original Medicare by employing AI, including machine learning, in conjunction with human clinical review. The model targets services believed to be vulnerable to overuse, fraud, and abuse, such as certain skin and tissue substitutes, electrical nerve stimulator implants, and knee arthroscopy for osteoarthritis.
While prior authorization has been a common feature in Medicare Advantage plans, its deployment in original Medicare has been less frequent. The introduction of WISeR marks a significant shift, and its potential impact on patient access is a subject of intense scrutiny. Federal government reports, such as those from the HHS Office of Inspector General (OIG), have previously raised concerns about Medicare Advantage plans denying beneficiaries access to services even when they appear to meet coverage rules. For instance, a 2022 OIG memorandum highlighted instances where over 10% of denials by Medicare Advantage plans were questionable, although it also noted that plans overturned 81% of denials upon appeal in 2024, indicating a potential for resolution through the appeals process.
The stated goal of the WISeR model, according to the Centers for Medicare and Medicaid Services (CMS), is to "ensure timely and appropriate Medicare payment for select items and services." However, critics view this initiative with considerable apprehension. Advocates for health insurance reform, such as Wendell Potter, have voiced concerns about the political motivations behind the model. Investigations by prominent news outlets have suggested that in the initial months of the WISeR pilot, delays in care and denials have occurred in some instances across the participating states. Furthermore, even with automated processes, healthcare providers can face a substantial administrative burden, including increased work related to managing denials.
Financial Incentives and Profit Motives
A critical aspect of the WISeR model involves the financial arrangements with participating vendors. These vendors, tasked with implementing AI-driven prior authorization, earn a share of what CMS terms "averted expenditures." This structure has raised concerns that vendors may be incentivized to reject care requests to generate revenue, echoing long-standing criticisms of profit-making models that potentially discourage patients from accessing medically necessary care. Several lawmakers have introduced resolutions and amendments aimed at blocking funding for the WISeR model, citing significant threats to patient access and the potential for a system that prioritizes financial gain over patient well-being.
Adding to the complexity, the Trump administration appears to hold a somewhat bifurcated approach to prior authorization. While expanding its use in original Medicare via AI through WISeR, CMS also aims to reduce and streamline its application by private insurers, including Medicare Advantage plans. CMS Administrator Mehmet Oz has issued warnings to insurance executives, stating that if they do not voluntarily ease the burden of prior authorization, the federal government will impose regulations. This dual approach suggests a desire to leverage AI for efficiency while simultaneously pushing for broader systemic reforms to improve patient access.
In response to these pressures, health plans have released data indicating a reduction in prior authorization requests. An industry-wide survey suggests that between June 2025 and April 2026, requests declined by 11 percent. However, it remains unclear whether this reduction is accompanied by a corresponding decrease in denial rates. Health plans have also pledged greater transparency regarding the clinical reasoning behind prior authorization decisions and have assured that AI or algorithms are not used in isolation to deny requests involving medical necessity or clinical considerations. These assurances aim to alleviate concerns about the absence of human oversight in AI-driven decisions.
The Road Ahead: Balancing Innovation and Patient Care
The debate surrounding AI in prior authorization highlights a fundamental tension between the potential for technological innovation to improve efficiency and the imperative to ensure that patient care remains the paramount concern. While AI offers the promise of streamlining approvals, reducing administrative waste, and potentially freeing up clinicians’ time for direct patient interaction, the current trajectory raises questions about whether this potential is being fully realized.
Jared Dashevsky, a physician and founder of Healthcare Huddle, has articulated a common concern: "AI could eliminate barriers, reduce administrative waste, give us more time with patients. But that’s not what’s being built." He suggests that the current focus may be on an "arms race to deny faster and appeal faster," essentially automating a flawed system rather than fundamentally redesigning it.
The ongoing pilots and policy discussions underscore the critical need for robust oversight, transparency, and a commitment to ethical implementation. As AI becomes more integrated into healthcare decision-making, ensuring that these technologies serve to enhance patient access and outcomes, rather than create new obstacles, will be a defining challenge for the healthcare industry and policymakers alike. The success of initiatives like WISeR will ultimately be judged not only by their impact on spending but, more importantly, by their effect on the timely and equitable delivery of necessary medical care to all Americans. The journey to reform prior authorization is complex, and the role of AI within it remains a subject of intense observation and debate.
